Raynaud Phenomenon
19
1
1
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.5%
2 terminated out of 19 trials
81.8%
-4.7% vs benchmark
16%
3 trials in Phase 3/4
78%
7 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (19)
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
Apollo Device for Fatigue in Systemic Sclerosis
Botulinum Toxin in Raynaud's Phenomenon
Application for Monitoring and Evaluation of Raynaud's Phenomenon
Cold Challenge With C21 in RP
Phototherapy For Treatment Of Raynaud's Phenomenon
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
Dermoscopy in Primary Raynaud's Phenomenon
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Follow-up of SPTS in Patients With Raynaud's Phenomenon
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
Tadalafil-Delivra and Raynaud's Phenomenon
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon